

# Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 624 • July 2016

## Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Gentamicin 40 mg/ml Injection (DIN 02242652), manufactured by Sandoz Canada Inc., Gentamicin (E) 1.6 mg/ml Injection (DIN 02082152), manufactured by Baxter Corporation, was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Gentamicin 40 mg/ml Injection (DIN 02242652) has been resolved.

As a result, Gentamicin (E) 1.6 mg/ml Injection (DIN 02082152) will no longer be considered a temporary benefit for the *ADBL* **after August 8, 2016**.

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)  
**FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.624 2016/07

